Bernard J. Zovighian Acquires 580 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) CEO Bernard J. Zovighian purchased 580 shares of the stock in a transaction on Monday, May 6th. The shares were bought at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Edwards Lifesciences Trading Down 0.9 %

Shares of NYSE EW opened at $85.09 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The business’s 50 day moving average is $90.05 and its two-hundred day moving average is $79.69. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The stock has a market capitalization of $51.28 billion, a P/E ratio of 36.68, a PEG ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EW. DSM Capital Partners LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $28,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $34,000. Riverview Trust Co acquired a new stake in Edwards Lifesciences in the 1st quarter valued at approximately $34,000. Pingora Partners LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $38,000. Finally, Operose Advisors LLC increased its holdings in Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Piper Sandler lifted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday, April 26th. Morgan Stanley boosted their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Barclays upped their price objective on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research note on Tuesday. Evercore ISI decreased their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday, April 26th. Finally, Mizuho upped their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $93.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.